Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders held by Second Sight Medical Products, Inc. on May 10, 2016, in Valencia, California. The filing details the voting results for director elections, equity plan amendments, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Of the 36,019,086 shares entitled to vote, 30,161,225 shares (83.74%) were represented at the meeting. The following matters were approved:
- Proposal 1 (Director Elections): All six nominees (Will McGuire, Robert J. Greenberg, William J. Link, Aaron Mendelsohn, Matthew Pfeffer, and Gregg Williams) were elected to the Board of Directors.
- Proposal 2 (Equity Incentive Plan Amendments): Stockholders approved amendments to the 2011 Equity Incentive Plan to:
- Increase the maximum number of issuable shares from 6,000,000 to 7,500,000.
- Add the ability to grant restricted stock units (RSUs).
- Permit the Company to reprice or exchange outstanding options at its discretion.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of Gumbiner Savett Inc. as the independent registered public accounting firm for the year ending December 31, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely as a record of the stockholder vote.
Key Facts for Investor Verification
- Verify the impact of the new option repricing authority on future dilution and employee compensation costs.
- Confirm the total number of shares authorized under the amended 2011 Equity Incentive Plan (7,500,000).
- Note the high level of broker non-votes (5,474,574) on director elections, indicating shares held by brokers that did not receive instructions.
- Review the full Proxy Statement filed on April 15, 2016, for detailed biographies of directors and further context on the equity plan changes.